Skip to main content

Ascendis Pharma (ASND) Gets a Buy from Morgan Stanley

Tipranks - Tipranks - Wed Mar 11, 5:39AM CDT

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma yesterday and set a price target of $256.00. The company’s shares closed yesterday at $239.92.

Claim 70% Off TipRanks Premium

According to TipRanks, Skor is a 5-star analyst with an average return of 18.8% and a 63.41% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Pharvaris, and Cytokinetics.

In addition to Morgan Stanley, Ascendis Pharma also received a Buy from TipRanks – Google’s Google Biotechnology in a report issued today. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Ascendis Pharma (NASDAQ: ASND).

See the top stocks recommended by analysts >>

Based on Ascendis Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $245.18 million and a GAAP net loss of $33.25 million. In comparison, last year the company earned a revenue of $173.92 million and had a GAAP net loss of $38.47 million

Read More on ASND:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).